Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 401–500 of 1,006
Changes in hormones and biomarkers in polycystic ovarian syndrome treated with gastric bypass
Eid, G. M., McCloskey, C. A., Titchner, R. L., Korytkowski, M. T., Gross, D., Grabowski, C., & Wilson, M. A. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.02.046 · Cited by 50
“These biomarker abnormalities may be interrelated as hyperinsulinemia increases LH-dependent androgen production [7,8], and androgens contribute to insulin resistance [9].”
BackgroundZhu, Q., Zuo, R.-J., He, Y., Wang, Y., Chen, Z., Sun, Y. W., & Sun, K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3899 · Cited by 50
“The incidence of IR is about 50%–70% in PCOS patients and is higher in PCOS patients with obesity (2).”
BackgroundBenrick, A., Kokosar, M., Hu, M., Larsson, M., Maliqueo, M. A., Marcondes, R. R., Soligo, M., Protto, V., Jerlhag, E., Sazonova, A., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601381r · Cited by 50
THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0585 · Cited by 49
Role of androgens and androgen receptor in control of mitochondrial function
Ahmad, I., & Newell‐Fugate, A. E. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00205.2022 · Cited by 49
Vitale, S. G., Fulghesu, A. M., Mikuš, M., Watrowski, R., D’Alterio, M. N., Lin, L., Shah, M., Reyes-Muñoz, E., Sathyapalan, T., & Angioni, S. L. (2022) · Biomedicines · doi:10.3390/biomedicines10081816 · Cited by 49
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease
Dubey, P., Reddy, S., Sharma, K., Johnson, S., Hardy, G., & Dwivedi, A. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02050-5 · Cited by 52
“Hyperandrogenism exacerbates insulin resistance via altered adipokine secretion and insulin signaling pathways in skeletal muscle and adipose tissue [101].”
Di Sarra, D., Tosi, F., Bonin, C., Fiers, T., Kaufman, J.-M., Signori, C., Zambotti, F., Dall'Alda, M., Caruso, B., Zanolin, M. E., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1161 · Cited by 47
“Insulin resistance and the associated metabolic abnormalities are frequent findings in women with polycystic ovary syndrome (PCOS) (5).”
BackgroundPrenatal programming: adverse cardiac programming by gestational testosterone excess
Vyas, A. K., Hoang, V., Padmanabhan, V., Gilbreath, E., & Mietelka, K. A. (2016) · Scientific Reports · doi:10.1038/srep28335 · Cited by 49
Yao, K., Bian, C., & Zhao, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4642 · Cited by 49
“Insulin resistance (IR) and associated metabolic abnormalities appear to play a significant role in the development of PCOS and in sustaining this disorder (2,3).”
A regulatory role of androgen in ovarian steroidogenesis by rat granulosa cells
Hasegawa, T., Kamada, Y., Hosoya, T., Fujita, S., Nishiyama, Y., Iwata, N., Hiramatsu, Y., & Otsuka, F. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.002 · Cited by 50
“In patients with polycystic ovary syndrome (PCOS), endogenous insulin levels are increased due to insulin resistance [1].”
BackgroundCunningham, T. K., Allgar, V. L., Dargham, S. R., Kilpatrick, E. S., Sathyapalan, T., Maguiness, S. D., Rudin, H. R. M., Ghani, N. M. A., Latiff, A. A., & Atkin, S. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00013 · Cited by 49
Mercury leads to features of polycystic ovary syndrome in rats
Merlo, E., Schereider, I. R. G., Simões, M. R., Vassallo, D. V., & Graceli, J. B. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.05.006 · Cited by 49
Makrinou, E., Drong, A., Christopoulos, G., Lerner, A., Chapa-Chorda, I., Karaderi, T., Lavery, S. A., Hardy, K., Lindgren, C. M., & Franks, S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110611 · Cited by 49
Bisphenol-A and polycystic ovary syndrome: a review of the literature
Kechagias, K. S., Semertzidou, A., Athanasiou, A., Paraskevaidi, M., & Kyrgiou, M. (2020) · Reviews on Environmental Health · doi:10.1515/reveh-2020-0032 · Cited by 49
“Familial distribution of PCOS patients suggests that genetics play an important role in the development of the syndrome and around 250 different candidate genes have been identified in databases and linked with PCOS [5, 6].”
BackgroundCai, M., Shao, X., Xing, F., Zhang, Y., Gao, X., Zeng, Q., Dilimulati, D., Qu, S., & Zhang, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14583 · Cited by 51
“Insulin resistance affects 50% to 80% of women with PCOS, depending on the population and diagnostic method used,(2,3) and plays an intrinsic role in the pathogenesis of PCOS, independently of obesity.(6,7) Previous studies have demonstrated that IR may bring about hyperandrogenaemia by disrupting the hypothalamic-pit…”
BackgroundSíndrome de ovario poliquístico. diagnóstico y manejo
Sir, P. T., Preisler, R. J., & Magendzo, N. A. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70229-3 · Cited by 49
Vassilatou, E., Vassiliadi, D. A., Salambasis, K., Lazaridou, H., Koutsomitopoulos, N., Kelekis, N., Kassanos, D., Hadjidakis, D., & Dimitriadis, G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0567 · Cited by 43
Reyes-Muñoz, E., Ortega-González, C., Martínez-Cruz, N., Arce-Sánchez, L., Estrada‐Gutiérrez, G., Morán, C., Sánchez-Serrano, A. P., Higareda-Sánchez, R., & la Jara-Díaz, J. F. D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012107 · Cited by 51
“involve a unique disorder of insulin action secondary to decreased insulin receptor signalling, likely caused by serine hyperphosphorylation of the receptor and of the insulin receptor substrate 1.(7) Thus, 50% of women present an activity that inhibits autophosphorylation of the tyrosine kinase receptor of insulin.”
BackgroundPolak, A. M., Adamska, A., Krentowska, A., Łebkowska, A., Hryniewicka, J., Adamski, M., & Kowalska, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030732 · Cited by 48
“Previous studies [2,26,28] confirmed that metabolic abnormalities are less severe in normoandrogenic women with PCOS in comparison to phenotypes with hyperandrogenism.”
BackgroundResultPolycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance
Genazzani, A. D., & Genazzani, A. R. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.71 · Cited by 48
Liu, Z., Hao, C., Song, D., Zhang, N., Bao, H., & Qu, Q. (2015) · Reproductive Sciences · doi:10.1177/1933719114565037 · Cited by 48
“Insulin promotes the synthesis of androgen in thecal cells directly.(50) This is the reason why BMI, HOMA-IR, and age should be adjusted when establishing the presence of hyperandrogenemia in women.”
BackgroundChen, Y., Zhang, X., Huang, J., Zhou, S., Liu, F., Jiang, L., Chen, M., Wan, J., & Yang, D. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.01.025 · Cited by 48
Alviggi, C., Conforti, A., De Rosa, P., Strina, I., Palomba, S., Vallone, R., Gizzo, S., Borrelli, R., Andersen, C. Y., De Placido, G., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00117 · Cited by 41
Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
Ruan, X., Li, M., & Mueck, A. O. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130104922 · Cited by 43
Polycystic ovary syndrome in adolescents
Dabadghao, P. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.006 · Cited by 35
Tang, L., Yuan, L., Yang, G., Wang, F., Fu, M., Chen, M., & Liu, D. (2019) · Clinical Endocrinology · doi:10.1111/cen.14056 · Cited by 45
Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome
Deniz, R., Yavuzkır, Ş., Uğur, K., Üstebay, D. Ü., Baykuş, Y., Üstebay, S., & Aydın, S. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1758926 · Cited by 48
“High levels of lipid, insulin, insulin resistance, and glucose levels confirm previously reported studies (Diamanti-Kandarakis and Dunaif 2012; Ebrahimi-Mamaghani et al. 2015).”
ResultSudhakaran, G., Guru, A., Haridevamuthu, B., Murugan, R., Arshad, A., & Arockiaraj, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120276 · Cited by 48
Management strategy of infertility in polycystic ovary syndrome
Li, M., Ruan, X., & Mueck, A. O. (2022) · Global Health Journal · doi:10.1016/j.glohj.2022.03.002 · Cited by 48
Li, X., & Shao, R. (2014) · Europe PMC (PubMed Central) · Cited by 48
Advani, K., Batra, M., Tajpuriya, S., Gupta, R., Saraswat, A., Nagar, H. D., Makwana, L., Kshirsagar, S., Kaul, P., Ghosh, A. K., et al. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1604644 · Cited by 49
Papalou, O., & Diamanti-Kandarakis, E. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1266250 · Cited by 47
“However, which of the above mechanisms dominates has not yet been elucidated [5].”
BackgroundInfluentialSelf-citationvan der Ham, K., Moolhuijsen, L. M. E., Brewer, K., Sisk, R. K., Dunaif, A. E., Laven, J. S. E., Louwers, Y. V., & Visser, J. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae298 · Cited by 47
Self-citationUnraveling the gut microbiota’s role in PCOS: a new frontier in metabolic health
Li, C., Cheng, D., Ren, H., & Zhang, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1529703 · Cited by 48
Rubin, K. H., Glintborg, D., Nybo, M., Andersen, M., & Abrahamsen, B. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2737 · Cited by 47
“Increased secretion of interleukins and chemokines and decreased adiponectin levels in PCOS may link central obesity, inflammatory risk, and insulin resistance.((6,38)) Our finding of reduced fracture rate in PCOS suggests that the potential negative effects on bone of visceral obesity, the associated low growth hormo…”
BackgroundLivadas, S., Κόλλιας, Α., Panidis, D., & Diamanti‐Kandarakis, E. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1007 · Cited by 47
Self-citationPrenatal androgen excess programs metabolic derangements in pubertal female rats
Yan, X., Dai, X., Wang, J., Zhao, N., Cui, Y., & Liu, J. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0577 · Cited by 49
Xiang, Y., Song, Y., Li, Y., Zhao, D., Ma, L., & Tan, L. (2016) · Medical Science Monitor · doi:10.12659/msm.897301 · Cited by 47
Ruan, X., Kubba, A., Aguilar, A., & Mueck, A. O. (2017) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2017.1317735 · Cited by 47
Mogili, K. D., Karuppusami, R., Thomas, S. V., Chandy, A., Kamath, M. S., & Tk, A. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.08.001 · Cited by 47
Januszewski, M., Issat, T., Jakimiuk, A. A., Santor-Zaczyńska, M., & Jakimiuk, A. J. (2019) · Ginekologia Polska · doi:10.5603/gp.2019.0002 · Cited by 47
Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism
Męczekalski, B., Szeliga, A., Maciejewska-Jeske, M., Podfigurna, A., Cornetti, P., Bala, G., & Adashi, E. Y. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1903419 · Cited by 47
“Insulin in conjunction with LH upregulate CYP17, subsequently increasing testosterone production [13,14].”
BackgroundAlmario, R. U., & Karakas, S. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1384521 · Cited by 47
Targets to treat metabolic syndrome in polycystic ovary syndrome
Mahalingaiah, S., & Diamanti-Kandarakis, E. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1101067 · Cited by 43
“Insulin resistance has been demonstrated in many target tissues such as skeletal muscle, fibroblasts and adipose tissue with abnormalities suggested in insulin receptors and post-receptor signaling.[80,81] Counter to the insulin resistance noted in peripheral tissues, ovarian insulin responsiveness has remained intact…”
BackgroundSelf-citationCardiovascular risk factors and events in women with androgen excess
Μacut, D., Antić, I. B., & Bjekić-Macut, J. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0215-1 · Cited by 47
Kabakchieva, P., Gateva, A., Velikova, T. V., Georgiev, T., Yamanishi, K., Okamura, H., & Kamenov, Z. A. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000442 · Cited by 46
“Most women with PCOS have obesity and insulin resistance (IR) (3,4) that further increases the risk for type 2 diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and metabolic syndrome (5-7).”
BackgroundJiang, X., Tai, H., Xiao, X.-S., Zhang, S., Cui, S.-C., Qi, S.-B., Hu, D., Zhang, L.-N., Kuang, J., Meng, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.962154 · Cited by 46
The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome
Sivanandy, M. S., & Ha, S. K. (2023) · Diagnostics · doi:10.3390/diagnostics13050907 · Cited by 46
“Although PCOS can present with multiple different symptomatology, at a National Institutes of Health (NIH)-sponsored conference on PCOS in 1990, attendees voted highly for hyperandrogenism and chronic anovulation as potential diagnostic features for PCOS [18].”
InfluentialHyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Hirschberg, A. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad590 · Cited by 47
Ni, X., Sun, Z.-J., Hu, G.-H., & Wang, R. (2015) · Reproductive Sciences · doi:10.1177/1933719114549852 · Cited by 46
Amato, M. C., Guarnotta, V., Forti, D., Donatelli, M., Dolcimascolo, S., & Giordano, C. (2013) · Human Reproduction · doi:10.1093/humrep/det105 · Cited by 38
“…increased prevalence of classical and non-classical cardiovascular risk factors and changes in potential modulators of cardiometabolic risk have been well documented (Amato et al., 2008; Galluzzo et al., 2008; Hoffman and Ehrmann, 2008; Diamanti-Kandarakis and Dunaif, 2012; Randeva et al., 2012).”
BackgroundDalamaga, Μ., Papadavid, E., Basios, G., Vaggopoulos, V., Rigopoulos, D., Kassanos, D., & Trakakis, E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.014 · Cited by 46
Li, A., Lu, Z., Jiajia, J., Yang, N., Ying, L., Lingbo, C., Yugui, C., Feiyang, D., Han, X., Jiayin, L., et al. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20170136 · Cited by 46
Polycystic ovary syndrome in adult women
Ortiz-Flores, A. E., Luque-Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.02.019 · Cited by 37
Abbott, D. H., Rogers, J., Dumesic, D. A., & Levine, J. E. (2019) · Medical Sciences · doi:10.3390/medsci7120107 · Cited by 47
Racial and ethnic differences in the metabolic response of polycystic ovary syndrome
Ezeh, U. I., Chen, Y.-D. I., & Azziz, R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14193 · Cited by 46
Wu, C.-H., Chiu, L., Chang, Y., Lee, C., Lee, M., Lee, T., & Wei, J. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.574651 · Cited by 46
The role of miRNAs in polycystic ovary syndrome with insulin resistance
Luo, Y., Cui, C., Han, X., Wang, Q., & Zhang, C. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-02019-7 · Cited by 46
“Thus, hyperinsulinism contributes to clinical manifestations, including ovulatory disturbances [13], menstrual irregularity, anovulatory infertility, and immature follicles increase [14] in PCOS.”
BackgroundPorchia, L. M., Hernandez-Garcia, S. C., Gonzalez-Mejia, M. E., & López-Bayghen, E. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.03.010 · Cited by 45
Parker, J. (2023) · Life · doi:10.3390/life13041056 · Cited by 47
Polycystic Ovary Syndrome as a Paradigm for Prehypertension, Prediabetes, and Preobesity
Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0500-6 · Cited by 45
Chaudhari, N., & Nampoothiri, L. P. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0035 · Cited by 45
“In addition to its gynecological anomalies, PCOS is also associated with several metabolic disorders with a high prevalence rate of 30%–60% for obesity [2] and 50%–70% for insulin resistance [3].”
BackgroundZhang, L., Fang, X., Li, L., Liu, R., Zhang, C., Liu, H., Tan, M., & Yang, G. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0902-4 · Cited by 45
Pradas, I., Rovira‐Llopis, S., Naudí, A., Bañuls, C., Rocha, M., Hernández‐Mijares, A., Pamplona, R., Víctor, V. M., & Jové, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52263-w · Cited by 45
Varlamov, O., Chu, M. P., McGee, W. K., Cameron, J. L., O'Rourke, R. W., Meyer, K. A., Bishop, C. V., Stouffer, R. L., & Roberts, C. T. (2013) · Endocrinology · doi:10.1210/en.2013-1428 · Cited by 44
Yu, J., Ma, Y., Wu, Z., Li, Y., Tang, L., Li, Y., & Deng, B. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3396-0 · Cited by 45
“PCOS, a common endocrine disorder, is characterized by menstrual irregularities, infertility, clinical and biochemical hyperandrogenism, ovarian enlargement, abnormal gonadotropin secretory dynamics, obesity and insulin resistance, which do not coexist in all women diagnosed with PCOS [3, 4].”
BackgroundMethodSerum LBP Is Associated with Insulin Resistance in Women with PCOS
Zhu, Q., Zhou, H., Zhang, A., Gao, R., Yang, S., Zhao, C., Wang, Y., Hu, J., Goswami, R., Gong, L., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0145337 · Cited by 39
Ramos, F., Lara, L., Kogure, G., Silva, R., Ferriani, R., Silva de Sá, M., & Reis, R. (2016) · Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics · doi:10.1055/s-0036-1585457 · Cited by 37
Jiao, X., Chen, W., Zhang, J., Wang, W., Song, J., Chen, D., Zhu, W., Shi, Y., & Yu, X. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00504 · Cited by 45
Evolutionary origins of polycystic ovary syndrome: An environmental mismatch disorder
Charifson, M. A., & Trumble, B. C. (2019) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoz011 · Cited by 44
“Additionally, 50% of females with PCOS have a defect in the insulin-pathway downstream of the receptor in the ovaries that may contribute to PCOS [28].”
BackgroundInfluentialSørensen, A. E., Udesen, P. B., Maciag, G. J., Geiger, J., Saliani, N., Januszewski, A. S., Jiang, G., Ronald, C. W., Hardikar, A. A., Wissing, M. L., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00242 · Cited by 44
“It is well established that PCOS is associated with defects in insulin secretion and profound insulin resistance (45).”
BackgroundChen, Y., Guo, J., Zhang, Q., & Zhang, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.853473 · Cited by 45
Singh, R., Kaur, S., Yadav, S., & Bhatia, S. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.02.002 · Cited by 44
Ovarian and extra-ovarian mediators in the development of polycystic ovary syndrome
Puttabyatappa, M., & Padmanabhan, V. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0079 · Cited by 43
Jabbour, R., Ott, J., Eppel, W., & Frigo, P. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232299 · Cited by 43
“This state is characterized by IR in skeletal muscle, adipose tissue and liver, due to a post-binding defect in insulin receptor signaling caused by increased serine phosphorylation of the insulin receptor and the insulin receptor substrate-1 (IRS-1), but ovarian hypersensitivity to insulin [6,8].”
BackgroundKaramali, M., Kashanian, M., Alaeinasab, S., & Asemi, Z. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12545 · Cited by 43
Nishiyama, Y., Hasegawa, T., Fujita, S., Iwata, N., Nagao, S., Hosoya, T., Inagaki, K., Wada, J., & Otsuka, F. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.004 · Cited by 43
“Since insulin resistance is considered to play an important role in the pathogenesis of polycystic ovary syndrome (PCOS) [4], attention has been paid to the altered pattern of incretin secretion and the insulinotropic activity of incretins in diabetic, obese [2, 5-7], and PCOS patients [8].”
BackgroundLi, M., Gao, S., Kang, M., Zhang, X., Ping, L. A. N., Wu, X., Xiaofei, Y. A. N., Dang, H., & Zheng, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154908 · Cited by 43
Kim, J. Y., Tfayli, H. M., Michaliszyn, S. F., Lee, S., & Arslanian, S. A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.02.004 · Cited by 43
“PCOS is not only a hormonal and reproductive disorder, but also a cluster of metabolic abnormalities driven by insulin resistance and hyperinsulinemia in the presence or absence of obesity (25, 26).”
BackgroundTorchen, L. C., Kumar, A., Kalra, B., Savjani, G., Sisk, R., Legro, R. S., & Dunaif, A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.03.029 · Cited by 39
“The diagnosis of PCOS was made in the probands using the NIH criteria (1) of an elevation of circulating testosterone (T) and/or non-sex hormone binding globulin bound (uT) levels associated with chronic oligomenorrhea (≤6 menses per year) as reported (6).”
Self-citationPolycystic ovary syndrome and the risk of cardiometabolic complications in longitudinal studies
Jacewicz‐Święcka, M., & Kowalska, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3054 · Cited by 38
Xie, L., Zhang, D., Ma, H., He, H. R., Xia, Q., Shen, W., Chang, H., Deng, Y., Wu, Q., Cong, J., et al. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/7918631 · Cited by 43
“Insulin resistance has an important role in the mechanism of PCOS in both obese and nonobese women, and hyperinsulinemia in response to insulin resistance increases ovarian androgen synthesis and decreases hepatic sex-hormone binding globulin (SHBG) synthesis resulting in androgen excess [3].”
BackgroundJia, C., Wang, S., Yin, C., Liu, L., Zhou, L., & Ma, Y. (2020) · Gene · doi:10.1016/j.gene.2020.144591 · Cited by 43
Quercetin and polycystic ovary syndrome
Ma, C., Xiang, Q., Song, G., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1006678 · Cited by 43
Plasma L -carnitine levels of obese and non-obese polycystic ovary syndrome patients
Çelik, F., Köse, M., Yılmazer, M., Köken, G., Arıöz, D. T., & Pektas, M. K. (2017) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2016.1264375 · Cited by 43
“That is, insulin-sensitising drugs have been able to cause a significant reduction in fasting insulin levels and concurrently significant improvement in biochemical and/or clinical hyperandrogenism (Diamanti-Kandarakis et al. 2006; Diamanti-Kandarakis and Dunaif 2012).”
BackgroundPuttabyatappa, M., Andriessen, V., Mesquitta, M., Zeng, L., Pennathur, S., & Padmanabhan, V. (2017) · Endocrinology · doi:10.1210/en.2017-00460 · Cited by 42
“cluding exposure to excess native steroids during disease states (5) and environmental endocrine-disrupting”
BackgroundAydos, A., Gurel, A., Islakoğlu, Y. Ö., Noyan, S., Gokce, B., Ecemiş, T., Kaya, C., Aksu, A. T., & Dedeoğlu, B. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168875 · Cited by 43
The association of the lipidomic profile with features of polycystic ovary syndrome
Moran, L., Mundra, P. A., Teede, H. J., & Meikle, P. J. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0023 · Cited by 42
Pittenger, S. R., Kao, C., Pasch, L. A., Shinkai, K., Cedars, M. I., & Huddleston, H. G. (2017) · Fertility Research and Practice · doi:10.1186/s40738-017-0035-z · Cited by 42
“metabolic phenotype and is compounded by obesity [8, 10].”
BackgroundLi, W., Chen, Q., Xie, Y., Hu, J., Yang, S., & Lin, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13860 · Cited by 44
Wang, C., Ding, C., Hua, Z., Chen, C.-Y., & Jia, Y. (2020) · Mediators of Inflammation · doi:10.1155/2020/8865647 · Cited by 44
“But more and more studies evidence that IR regulates multiple mediators and pathways and is critically involved in the pathogenesis and development of PCOS [2, 21].”
BackgroundHuang‐Doran, I., Kinzer, A. B., Jimenez‐Liñan, M., Thackray, K., Harris, J., Adams, C. L., de Kerdanet, M., Stears, A. J., O’Rahilly, S., Savage, D. B., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab275 · Cited by 42
“The p85 α regulatory subunit of PI3-kinase interacts with phosphorylated IRS proteins, activating and approximating the p110 catalytic subunit to the plasma membrane, resulting in appearance of the phospholipid second messenger phosphatidylinositol (3-5)-trisphosphate (PIP3).”
BackgroundMethodInfluentialRehman, K., Haider, K., & Akash, M. S. H. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174410 · Cited by 42
Visfatin and Resistin Serum Levels in Normal-Weight and Obese Women With Polycystic Ovary Syndrome
Farshchian, F., Tehrani, F. R., Amirrasouli, H., Pour, H. R., Hedayati, M., Kazerouni, F., & Soltani, A. (2014) · Intern J Endocrinol Metab · doi:10.5812/ijem.15503 · Cited by 42
“Thus, PCOS can lead to an increased risk of developing type 2 diabetes mellitus and cardiovascular disease (4).”
BackgroundNasri, K., Hantoushzadeh, S., Aghadavod, E., Taghizadeh, M., & Asemi, Z. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0042-122782 · Cited by 44
“The prevalence of insulin resistance in PCOS women ranges from 44 to 70 % [4].”
BackgroundModarres, S. Z., Heidar, Z., Foroozanfard, F., Rahmati, Z., Aghadavod, E., & Asemi, Z. (2017) · Biological Trace Element Research · doi:10.1007/s12011-017-1148-2 · Cited by 42
“Since insulin resistance and dyslipidemia in PCOS women contribute to both reproductive and metabolic disorders [17], it is important to identify methods to decrease complications related to insulin resistance and dyslipidemia through lifestyle changes and pharmacological interventions.”
BackgroundAlternative splicing of DENND1A, a PCOS candidate gene, generates variant 2
Tee, M. K., Speek, M., Legeza, B., Modi, B., Teves, M. E., McAllister, J. M., Strauss, J. F., & Miller, W. L. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.011 · Cited by 36
“PCOS is associated with hyperandrogenemia, hyperandrogenism, anovulation, infertility, and multiple small subcortical ovarian follicular “cysts” (2,3).”
BackgroundZhao, D., Qu, Q., Dai, H., Liu, Y., Jiang, L., Huang, X. Y., & Hao, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7890 · Cited by 41
“Under basal conditions, GLUT1 and GLUT4 are localized into intracellular vesicles and glucose uptake is completed when the vesicles translocate to the cell surface (46).”
el Sharkwy, I. A. E., & El-Din, M. S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576622 · Cited by 41
“Insulin resistance and hyper-androgenism aggravate each other so; insulin-sensitizing drugs improve the biochemical and clinical features of PCOS [17].”
Retracted
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.